The Future Ai

For Arjun Gupta, a 28-year-old IT professional, it began with something ordinary, a persistent cough. In a country where tuberculosis remains widespread, the diagnosis came quickly, almost automatically. He was started on anti-tubercular treatment.He followed it diligently. For months. But the cough did not leave. The fatigue worsened. And somewhere between hope and routine, doubt quietly crept in. When Arjun nearly a year later chose to go through a recheck, his case demanded a second look, this time, a deeper one. Imaging and biopsy told a very different story: metastatic lung adenocarcinoma.For a young, non-smoker, the diagnosis was as unexpected as it was devastating. Initial molecular tests did not immediately offer a clear treatment pathway. In many such cases, the next step is conventional chemotherapy. But here, the team chose to go further.A comprehensive Next Generation Sequencing (NGS) test, one that scans hundreds of genes, was conducted. The results revealed something rare, but critical: a ROS1 gene fusion, a mutation seen in a small subset of lung cancer patients, often younger and non-smoking.“In young patients, especially non-smokers with lung cancer, we must go beyond standard testing. Comprehensive molecular profiling allows us to identify rare but highly actionable mutations that can completely change treatment outcomes,” said Dr. Moushumi Suryavanshi, Head – Molecular & Cytogenetics Laboratory, Amrita Hospital, Faridabad. Based on this finding, Arjun was started on entrectinib, a targeted ROS1 inhibitor. The treatment was striking in its simplicity. No chemotherapy cycles. No hospital admissions. Just one capsule a day, taken at home.But what made entrectinib particularly significant in his case was something far more critical: its ability to cross the blood-brain barrier. For patients with brain metastases, this is not a minor detail, it is often the difference between partial control and comprehensive treatment. Instead of controlling disease in the lung while the brain lesions progress silently, the drug works in both places. The response was swift, and remarkable.At just eight weeks:

His oncologist noted simply: “Clinically well, back to work, no neurological symptoms.”“Targeted therapies have transformed how we treat certain cancers. Instead of broadly attacking cells, we are now able to precisely inhibit the molecular drivers of the disease. In cases like this, the response can be both rapid and profound,” added Dr Suryavanshi. Four months earlier, Arjun had been confronting a diagnosis that, in his own words, felt like a sudden expiry date on his life. And then, quietly, life began returning. He regained strength. He went back to work. The fatigue lifted. The fear receded.A few months later, in Mysuru, under wedding lights and music, Arjun stood among his family, not as a patient, but as a brother. He attended his younger sister’s wedding. He danced at the reception.“When I was first told it could be cancer, it felt like everything had stopped. I had already spent months treating what I thought was TB, with no answers. Today, I’m back at work, spending time with my family, and living normally again. It still feels unreal that one pill a day could give me my life back,” said Arjun Gupta. Today, one year later, Arjun is stable and leading a full life. His story is not just about recovery, it reflects a larger shift in how cancer is understood and treated:

What changed Arjun’s journey was not just treatment, it was timely scientific insight.And increasingly, in oncology, that insight is proving to be the difference between uncertainty and survival.